Friday, 16 October 2026European Markets

LUMIBIRD Stock Bullish Momentum With A 9.22% Rise On Tuesday

Loading stream...

(vianews) - the market ended the session with lumibird (lbird.pa) jumping 9.22% to €15.40 on tuesday, following the last session's upward trend. cac 40 dropped 0.16% to €7,406.01, after three sequential sessions in a row of gains, on what was a somewhat negative trend exchanging session today.

about lumibird

lumibird sa designs, manufactures, and sells various lasers for the scientific, industrial, and medical applications worldwide. it operates in two segments, photonics and medical. the company offers solid-state and diode lasers, fiber lasers, fiber lasers/amplifiers and components, laser rangefinder and lidar wind doppler lidar, medical and ophthalmological equipment. its products are used in various applications, such as industrial and scientific, defense and space, and lidar sensors. the company was incorporated in 1970 and is headquartered in lannion, france.

earnings per share

as for profitability, lumibird has a trailing twelve months eps of €0.45.

pe ratio

lumibird has a trailing twelve months price to earnings ratio of 34.22. meaning, the purchaser of the share is investing €34.22 for every euro of annual earnings.

volatility

lumibird's last week, last month's, and last quarter's current intraday variation average was 1.72%, 0.23%, and 1.73%.

lumibird's highest amplitude of average volatility was 1.72% (last week), 2.13% (last month), and 1.73% (last quarter).

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, lumibird's stock is considered to be oversold (<=20).

more news about lumibird (lbird.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com